Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 5R44AI157074-03
Grant search
Key facts
Disease
UnspecifiedStart & end year
20222025Known Financial Commitments (USD)
$998,375Funder
National Institutes of Health (NIH)Principal Investigator
SENIOR SCIENTIST Colleen CooperResearch Location
United States of AmericaLead Research Institution
CELDARA MEDICAL, LLCResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Preclinical development of an important, broad-spectrum antibody for pandemic influenza